Atomi Financial Group Inc. Has $456,000 Stock Position in GSK plc (NYSE:GSK)

Atomi Financial Group Inc. cut its stake in shares of GSK plc (NYSE:GSK) by 14.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,490 shares of the pharmaceutical company’s stock after selling 2,273 shares during the period. Atomi Financial Group Inc.’s holdings in GSK were worth $456,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in GSK. EverSource Wealth Advisors LLC boosted its stake in GSK by 9.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company’s stock valued at $137,000 after purchasing an additional 303 shares during the period. AQR Capital Management LLC boosted its position in shares of GSK by 103.4% in the second quarter. AQR Capital Management LLC now owns 26,363 shares of the pharmaceutical company’s stock valued at $1,015,000 after acquiring an additional 13,403 shares during the period. Daymark Wealth Partners LLC acquired a new position in shares of GSK in the second quarter valued at about $988,000. Creative Planning increased its position in GSK by 4.8% during the second quarter. Creative Planning now owns 203,246 shares of the pharmaceutical company’s stock worth $7,825,000 after acquiring an additional 9,322 shares during the period. Finally, NewEdge Advisors LLC raised its stake in GSK by 61.9% in the 2nd quarter. NewEdge Advisors LLC now owns 70,048 shares of the pharmaceutical company’s stock worth $2,697,000 after purchasing an additional 26,793 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and cut their target price for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Six equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Trading Up 0.7 %

Shares of GSK stock opened at $34.29 on Friday. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The stock’s fifty day moving average price is $33.89 and its two-hundred day moving average price is $37.84. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The company has a market cap of $71.06 billion, a PE ratio of 22.26, a P/E/G ratio of 1.31 and a beta of 0.63.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, January 9th. Shareholders of record on Friday, November 15th were given a $0.3928 dividend. This represents a $1.57 dividend on an annualized basis and a yield of 4.58%. The ex-dividend date of this dividend was Friday, November 15th. This is a boost from GSK’s previous quarterly dividend of $0.38. GSK’s payout ratio is currently 96.10%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.